A defining 2026 milestone in the industry is the shift toward Neoadjuvant and Adjuvant usage. In 2026, the market is identifying a trend where Keytruda is used before surgery to shrink tumors (neoadjuvant) or after surgery (adjuvant) in lung and melanoma cases. This 2026 strategy is vital because it moves the drug from being a "last resort" for metastatic patients to a "curative-intent" tool for those in earlier stages of cancer. By 2026, clinical guidelines in India are increasingly reflecting these global standards, leading to a 12% increase in prescriptions for Stage II and Stage III cancers this year.

The expansion into earlier lines of therapy is a primary driver for the India Keytruda Market. In 2026, "Melanoma" remains a smaller niche compared to lung cancer, but it is recognized as the fastest-growing indication for early-stage immunotherapy. This 2026 movement is also being supported by Oncology Specialist Training, where a new generation of Indian doctors is being trained specifically in the management of "Immune-Related Adverse Events" (irAEs). The 2026 market proves that by catching cancer early and treating it aggressively with immunotherapy, India is slowly improving its national five-year survival rates.

Do you think that using expensive drugs like Keytruda in early-stage cancer is a better investment than using them only when the cancer has spread? Please leave a comment!

#EarlyDetection #CurativeTherapy #India2026 #MelanomaAwareness #OncologyInnovation